周邊動脈疾病市場規模、佔有率和成長分析（按類型、治療方法、疾病、給藥途徑、最終用戶和地區分類）—2026-2033年產業預測

預計到 2024 年，周邊動脈疾病(PAD) 市場規模將達到 58.5 億美元，到 2025 年將成長至 64.6 億美元，到 2033 年將成長至 142.5 億美元，在預測期（2026-2033 年）內，複合成長率為 10.4%。

市場調查顯示，美國約有650萬40歲以上族群患有周邊動脈疾病（PAD），男女均有患病，但非裔美國人的發生率明顯較高。人口老化是PAD盛行率上升的關鍵因素，因為血管疾病的風險會隨著老齡化的成長而增加。此外，除了人口結構的變化，PAD診斷和治療方案的技術創新和核准也在不斷成長。這些因素共同加劇了周邊動脈疾病的整體風險。人口老化、疾病發生率上升以及技術進步的結合，凸顯了美國醫療保健市場中與PAD相關的複雜且不斷變化的風險因素。

周邊動脈疾病市場促進因素

老年族群中糖尿病和高血壓盛行率的不斷上升是周邊動脈疾病（PAD）市場成長的關鍵促進因素。老年人發生血管併發症的風險尤其高，而這些慢性疾病的存在會顯著增加PAD的風險。糖尿病和高血壓會加速動脈狹窄和硬化，嚴重限制流向四肢的血液。因此，這些健康問題在老齡化人口中的日益增多直接影響著市場動態，並催生了對有效PAD治療方法和干涉措施日益成長的需求。

周邊動脈疾病市場限制因素

周邊動脈疾病(PAD) 的復發對其市場成長潛力構成重大挑戰。儘管治療方案不斷改進，但 PAD 復發的風險仍阻礙著市場的永續發展。此外，產業內的產品召回問題會進一步加劇這些挑戰。召回會削弱消費者信心，引起監管機構的關注，並需要採取糾正措施，這可能會阻礙整體市場的成長和穩定。為了有效克服這些障礙，相關人員必須攜手合作，共同應對與疾病管理和產品安全相關的複雜挑戰，從而促進周邊動脈疾病治療方案的持續進步。

周邊動脈疾病（PAD）市場趨勢

周邊動脈疾病(PAD) 市場呈現顯著上升趨勢，主要受疾病發生率上升和創新產品核准增加的推動。 PAD 病例激增凸顯了對先進診斷和治療方案的需求，從而推動了市場成長。醫療技術的不斷進步為應對 PAD 的多重挑戰開闢了新的解決方案，有助於改善患者照護和治療效果。此外，隨著監管機構不斷核准突破性療法，市場有望充分利用這些進展，為相關人員和醫療服務提供者創造一個繁榮的市場環境。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球周邊動脈疾病市場規模（按類型及複合年成長率分類）（2026-2033 年）

• 周邊血管血管成形術用氣球
• 斑塊調節裝置
• 外周支架
• 周邊導管
• 血流調節裝置
• 下腔靜脈（IVC）過濾器
• 末梢用配件

全球周邊動脈疾病市場規模（按治療方法和複合年成長率分類）（2026-2033 年）

• 裝置
  • 支架
  • 氣球
  • 動脈粥狀硬化斑塊切除術裝置
• 導管
  • 藥物釋放型導管
  • 球囊導管
  • 導管導引線
• 斑塊修飾裝置
• 血流調節裝置
• 其他

全球周邊動脈疾病市場規模（按疾病類型和複合年成長率分類）（2026-2033 年）

• 降血脂藥物
• 三重H療法
• 血糖調節器
• 血栓預防
• 強心劑
• 溶栓劑
• 抗發炎藥

全球周邊動脈疾病市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 腸外給藥
• 其他

全球周邊動脈疾病市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 門診手術診所

全球周邊動脈疾病市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Medtronic plc（Ireland）
• Abbott Laboratories（USA）
• Boston Scientific Corporation（USA）
• Becton, Dickinson and Company（BD）（USA）
• Philips（Netherlands）
• Terumo Corporation（Japan）
• Cook Medical（USA）
• Cardinal Health, Inc.（USA）
• B. Braun Melsungen AG（Germany）
• Getinge AB（Sweden）
• Merit Medical Systems, Inc.（USA）
• BIOTRONIK SE & Co. KG（Germany）
• Endologix, Inc.（USA）
• Gore Medical（USA）
• Penumbra, Inc.（USA）
• AngioDynamics, Inc.（USA）
• Johnson & Johnson（USA）
• Bayer AG（Germany）

結論與建議

Peripheral Artery Disease Market size was valued at USD 5.85 Billion in 2024 and is poised to grow from USD 6.46 Billion in 2025 to USD 14.25 Billion by 2033, growing at a CAGR of 10.4% during the forecast period (2026-2033).

Market insights reveal that around 6.5 million individuals aged 40 and older in the U.S. are impacted by Peripheral Artery Disease (PAD), affecting both genders with a notably higher incidence among African Americans. The aging population plays a critical role in the growing prevalence of PAD, as the risk of vascular diseases increases with age. Furthermore, the demographic shift is paralleled by a rise in innovations and approvals for diagnostics and treatment solutions for PAD. These elements converge to enhance the overall risk landscape for peripheral arterial disease. The combination of an aging populace, increasing disease rates, and technological advancements highlights the complex and evolving risk factors associated with PAD in the U.S. healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peripheral Artery Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peripheral Artery Disease Market Segments Analysis

Global Peripheral Artery Disease Market is segmented by Type, Treatment, Disease, Route of Administration, End User and region. Based on Type, the market is segmented into Peripheral Angioplasty Balloons, Plaque Modification Devices, Peripheral Stents, Peripheral Catheters, Hemodynamic Flow Alteration Devices, Inferior Vena Cava (IVC) Filters and Peripheral Accessories. Based on Treatment, the market is segmented into Device, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices and Others. Based on Disease, the market is segmented into Lipid Lowering Drugs, Triple-H Therapy, Glucose Regulating Drugs, Blood Clot Preventing Drugs,, Inotropes,, Thrombolytic Agents, and Anti-Inflammatory Agents. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals & Clinics and Ambulatory Surgical Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peripheral Artery Disease Market

The rising prevalence of elderly individuals affected by diabetes and hypertension is a crucial driving force behind the growth of the peripheral artery disease (PAD) market. Older adults are especially vulnerable to vascular complications, and the presence of these chronic conditions significantly heightens the risk of developing PAD. Diabetes and high blood pressure contribute to the narrowing and hardening of arteries, which severely restricts blood flow to the limbs. As a result, the increasing incidence of these health issues within the aging population is directly influencing market dynamics and creating a heightened demand for effective PAD treatments and interventions.

Restraints in the Peripheral Artery Disease Market

The recurring nature of peripheral artery disease (PAD) poses a significant challenge to the market's growth potential. Despite improvements in treatment options, the risk of PAD reappearing continues to hinder sustained market progression. Additionally, issues surrounding product recalls in the industry may further exacerbate these challenges. Such recalls can undermine consumer confidence, draw regulatory attention, and necessitate remedial actions, all of which can stifle overall market growth and stability. To effectively navigate these obstacles, stakeholders must collaboratively address the intricate issues related to managing the disease and ensuring product safety, thereby fostering ongoing advancements in solutions for peripheral artery disease.

Market Trends of the Peripheral Artery Disease Market

The Peripheral Artery Disease (PAD) market is witnessing a notable upward trend driven by the rising incidence of the condition alongside an influx of innovative product approvals. This surge in PAD cases underscores the demand for advanced diagnostic and therapeutic options, catalyzing market growth. The ongoing advancements in medical technologies are paving the way for new solutions that address the multifaceted challenges of PAD, enhancing patient care and outcomes. Furthermore, as regulatory bodies continue to endorse groundbreaking treatments, the market is expected to capitalize on these developments, fostering a landscape rich in opportunities for stakeholders and healthcare providers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peripheral Artery Disease Market Size by Type & CAGR (2026-2033)

• Market Overview
• Peripheral Angioplasty Balloons
• Plaque Modification Devices
• Peripheral Stents
• Peripheral Catheters
• Hemodynamic Flow Alteration Devices
• Inferior Vena Cava (IVC) Filters
• Peripheral Accessories

Global Peripheral Artery Disease Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Device
  • Stents
  • Balloons
  • Atherectomy Devices
• Catheters
  • Drug-Eluting Catheters
  • Balloon Catheters
  • Guidewires
• Plaque Modification Devices
• Hemodynamic Flow Alteration Devices
• Others

Global Peripheral Artery Disease Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Lipid Lowering Drugs
• Triple-H Therapy
• Glucose Regulating Drugs
• Blood Clot Preventing Drugs,
• Inotropes,
• Thrombolytic Agents,
• Anti-Inflammatory Agents

Global Peripheral Artery Disease Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Others

Global Peripheral Artery Disease Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Clinics

Global Peripheral Artery Disease Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Disease, Route of Administration, End User)
  • US
  • Canada
• Europe (Type, Treatment, Disease, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Disease, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Disease, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Disease, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOTRONIK SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endologix, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gore Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penumbra, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations